Are research peptides legal? A jurisdiction-by-jurisdiction reading
In every jurisdiction below, selling a peptide as a labelled laboratory reagent is not itself the regulated act — selling it as a medicine is. The legal question is not what the molecule is but what it is presented and intended for, with two exceptions that also control the ingredient directly: Australia through the Poisons Standard and Canada through the Prescription Drug List. Import is a separate act again, governed by separate rules.
6 jurisdictions · 11 tracked regulatory entries · feed current to 22 Jul 2026
The short answer
No jurisdiction covered here bans “research peptides” as a category, and none grants them a category of their own. Each one asks the same first question — is this being placed on the market as a medicine?— and answers it from the seller’s own presentation and intended use rather than from the label. Supplying, advertising or importing a peptide for human use crosses the line in the United States, the United Kingdom, the European Union, Canada, Australia and New Zealand alike. Australia and Canada go further and control certain ingredients directly, where relabelling has no effect at all.
What follows is a reading of what the named regulators publish, with every statement linked to its primary source. It is not legal advice and it assesses no particular transaction.
The four questions that actually decide it
Most answers to “are peptides legal” fail because they ask about the substance. The regimes below ask about the transaction. Four questions separate them, and they are worth keeping distinct, because a different answer to each produces a different outcome:
01
What is it being sold as?
Every regime below turns on presentation and intended use before it turns on chemistry. A substance offered as a laboratory reagent and a substance offered as a treatment are different legal objects even when they are the same molecule in the same vial. Regulators read the whole listing — the copy, the imagery, the testimonials a seller chooses to republish — not the disclaimer at the bottom of it.
02
Is the substance itself controlled there?
A minority of jurisdictions also regulate the ingredient directly. Australia schedules substances in the Poisons Standard; Canada lists prescription-only ingredients on the Prescription Drug List. Where a substance is controlled at ingredient level, no amount of relabelling reaches around it — and this is the question most buying guides skip.
03
Is it crossing a border?
Import is a separate legal act from sale and from possession, governed by separate rules and often a separate agency. A transaction can be unremarkable in the seller’s jurisdiction and stopped at the buyer’s. Personal-importation provisions exist in several of the countries below, but they are conditional allowances — commonly requiring a prescription and capping quantity — not general permissions.
04
Is sport involved?
Anti-doping rules are a private regulatory regime running alongside national law, and they reach conduct national law does not. Class S2 of the WADA Prohibited List covers peptide hormones, growth factors and related substances, and for an athlete or support person bound by those rules, possession alone is a violation independent of whether anything unlawful has occurred.
Permitted where not presented or supplied as a medicine
Offence to sell or supply an unapproved medicine
Limited personal allowance; prescription medicines restricted
A summary row is a summary. The statutory mechanism behind each one, and the source it comes from, is set out below.
Jurisdiction by jurisdiction
United States
Food and Drug Administration (FDA)
Federal Food, Drug, and Cosmetic Act
The FD&C Act defines a drug partly by intended use: an article intended to diagnose, cure, mitigate, treat or prevent disease, or to affect the structure or any function of the body, is a drug regardless of what it is called. Intended use is established from objective evidence — the label, the site copy, the marketing, the testimonials a seller republishes — not from a disclaimer alone.
That is the whole mechanism. A peptide offered as a laboratory reagent, with no human-use claim attached to it anywhere, is not being marketed as a drug. The same vial offered with a claim about what it does in people is an unapproved new drug, and the FDA treats it as misbranded. This is why sellers are careful with their copy, and why "research use only" appears on the label of substances no laboratory is buying.
The compounding lists are the second front. Under sections 503A and 503B the FDA publishes evaluations of bulk drug substances nominated for compounding, and several peptides tracked in this index have appeared in those evaluations — including in the category the agency concluded should not be compounded. A placement there does not make possession unlawful; it removes the legitimate pharmacy route that would otherwise exist.
Where the line sits: The line is the claim, not the molecule. Almost everything the FDA can act on begins with a statement about what a substance does in a human body.
Placeholder seed entry recording the source, not an event. The FDA maintains categorised lists of bulk drug substances nominated for use in compounding, including substances it has evaluated and placed in the category that may not be compounded. Several peptides tracked in this index have appeared in these evaluations. PepIndex records movements between categories here as they are observed; the linked page is the authoritative listing.
Placeholder seed entry recording the source, not an event. Shortage status for approved GLP-1 products materially affects this market: when an approved product is listed as in shortage, compounding of that substance becomes permissible under conditions, and demand shifts toward alternative supply. Resolution of a shortage reverses that. PepIndex records status changes here because they move the whole category.
Placeholder seed entry recording the source, not an event. The FDA publishes warning letters issued to firms, including sellers marketing unapproved products or making disease claims. Where a letter names a vendor tracked in this index, PepIndex records it here and links it from that vendor's profile. No vendor currently in the index has such a letter recorded against it.
The FDA proposed leaving semaglutide, tirzepatide and liraglutide off the 503B bulk drug substances list, finding no clinical need for outsourcing facilities to compound them from bulk now that the GLP-1 shortages are resolved. If finalized, the exclusion would close the last routine legal pathway for large-scale compounded GLP-1s and further narrow the supply of non-branded semaglutide and tirzepatide. The FDA took comments on the proposal through mid-2026 and is reviewing them; a final determination had not been published as of this writing.
The FDA issued warning letters to research-peptide sellers — among them Prime Sciences and Gram Peptides — offering products labeled 'GLP-1-R', 'GLP1-S' and 'GLP1-T' that the agency identified as retatrutide, an investigational drug with no approved product that cannot lawfully be compounded. The letters cite unapproved-new-drug and misbranding violations for promoting the peptides for human use behind 'research use only' labeling, part of a broader 2026 enforcement push against GLP-1 and peptide sellers that also produced dozens of letters to telehealth firms marketing compounded GLP-1s.
The FDA confirmed the semaglutide shortage was resolved and set deadlines for compounders to stop making copies of the branded GLP-1 drug. Because the exemption allowing 503A and 503B facilities to compound semaglutide depended on its shortage status, removal from the list narrows the legal space in which compounded and “research” semaglutide is supplied.
After a short reconsideration, the FDA reaffirmed that the tirzepatide shortage was over, again requiring compounders to wind down production of copies. As with semaglutide, removal from the shortage list removes the basis that permitted compounded tirzepatide, tightening the supply of versions sold outside the approved products.
The FDA warned SwissChems that its semaglutide and retatrutide products — sold as research chemicals but promoted for human weight and metabolic use — are unapproved new drugs and misbranded under the FD&C Act. It is one of a series of letters the agency has issued to vendors offering GLP-1 and research peptides directly to the public.
Medicines and Healthcare products Regulatory Agency (MHRA)
Human Medicines Regulations 2012
The UK test has two limbs and either one is enough. A product is a medicinal product by presentation if it is presented as having properties for treating or preventing disease, and by function if it is administered with a view to restoring, correcting or modifying a physiological function. The second limb is the one sellers underestimate: a substance can be a medicine in law without a single health claim being made about it.
Placing a medicinal product on the UK market without a marketing authorisation is an offence under the Human Medicines Regulations 2012, as is advertising one. The MHRA does not need to schedule a peptide to act; it needs only to conclude the product falls within the definition.
Melanotan II is the worked example in this index. The MHRA has stated its position on melanotan products repeatedly and has acted to remove them from sale over a period of years on the basis that they fall within the definition of a medicinal product. The compound page records that status; the regulatory feed records the source.
Where the line sits: Presentation and function are alternatives, not a two-part test. Saying nothing about effects does not put a product outside the definition.
Placeholder seed entry recording the source, not an event. The UK regulator has published guidance and enforcement positions on the supply of unlicensed medicines to the public, including substances marketed as research chemicals. Several compounds tracked here have been the subject of public statements. PepIndex records those affecting indexed compounds.
European Medicines Agency (EMA) and national regulators
Directive 2001/83/EC, as transposed nationally
Directive 2001/83/EC supplies the same by-presentation-or-by-function definition the UK inherited, and Article 6 provides that no medicinal product may be placed on the market of a member state without an authorisation. That much is uniform across the EEA.
What is not uniform is everything after it. The Directive is transposed into twenty-seven national statutes, enforced by national agencies, with different prosecution thresholds, different customs practice, and in several member states a separate body of national anti-doping law that reaches possession as well as supply. PepIndex does not index national criminal law, and the absence of a national line in the table above should be read as an absence of coverage, not as permission.
The EMA itself authorises products rather than policing sellers. Its register matters here for a narrower reason: it establishes whether the substance in a research-grade vial has an approved counterpart at all, and therefore whether the trial literature a reader finds describes the product being sold or a different one made to pharmaceutical standard.
Where the line sits: The EU-level rule is uniform; the enforcement that actually reaches a buyer or a seller is national, and this index does not track it.
Placeholder seed entry recording the source, not an event. The European Medicines Agency publishes decisions on marketing authorisation. Approval status matters to this index because it determines whether the substance in a research-grade vial has an approved counterpart at all — and therefore whether a published trial literature exists for a product that is not the one being sold.
The Food and Drugs Act defines a drug by intended use in substantially the same way, and the Food and Drug Regulations require an authorisation — a Drug Identification Number or a Notice of Compliance — before a drug is sold in Canada. Selling an unauthorised drug is the offence; the substance does not need to be separately controlled for that to be true.
Section 29.1 of the Act underpins the Prescription Drug List, the list of medicinal ingredients that make a product prescription-only when it contains them. Peptides with approved counterparts appear there. Checking that list is the concrete step available to a reader, because it names ingredients rather than brands.
Importation for personal use is governed by published guidance rather than by a general allowance, and Health Canada applies it narrowly to products that are unauthorised in Canada.
Where the line sits: Authorisation is required to sell a drug at all, and the Prescription Drug List decides which ingredients carry a prescription requirement on top of that.
This authority is not yet tracked in the regulatory feed. Read the absence as missing coverage, not as an absence of enforcement.
Therapeutic Goods Act 1989 and the Poisons Standard
Australia regulates the substance as well as the claim, which is what makes it the strictest regime in this list. The Therapeutic Goods Act 1989 requires therapeutic goods to be entered on the Australian Register of Therapeutic Goods before they are imported, supplied or exported, unless an exemption applies.
Layered on top of that is the Poisons Standard — the Standard for the Uniform Scheduling of Medicines and Poisons — which places substances into schedules according to the degree of control considered appropriate over their availability. Peptide hormones and growth factors commonly sit in Schedule 4, prescription-only. Scheduling attaches to the ingredient itself, so a seller cannot move a Schedule 4 substance outside its schedule by describing the product differently.
The Personal Importation Scheme is the pathway individuals ask about most often. It permits import of goods not on the ARTG under conditions, but where the medicine is prescription-only in Australia it requires a valid Australian prescription held at the time of importation, with quantity limits on top of that.
Where the line sits: Australia is where the research-chemical framing does the least work: scheduling attaches to the substance, whatever the vial is labelled.
No entries are recorded against this authority in the regulatory feed yet.
The Medicines Act 1981 makes it an offence to sell or supply a medicine that has no consent for distribution, and defines a medicine by reference to its therapeutic purpose. The structure is familiar by this point in the list: the description a seller chooses does not settle the classification.
Medsafe administers the Act and publishes the consent register, which is the checkable artefact — it records what has been approved for distribution in New Zealand and on what terms.
Where the line sits: Consent for distribution is the gate. Without it, supply is the offence whether or not the substance is separately controlled.
This authority is not yet tracked in the regulatory feed. Read the absence as missing coverage, not as an absence of enforcement.
Anti-doping rules are not national law and do not depend on it. They bind athletes and support personnel through their sport, and they reach conduct that is otherwise lawful everywhere in the table above. Class S2 of the World Anti-Doping Agency Prohibited List covers peptide hormones, growth factors, related substances and mimetics, and includes a catch-all clause capturing substances with no current approval for human therapeutic use. For anyone bound by those rules, possession is itself a violation — the question of whether a purchase was lawful never arises.
Placeholder seed entry recording the source, not an event. The World Anti-Doping Agency publishes an annual Prohibited List; class S2 covers peptide hormones, growth factors, related substances and mimetics. Several compounds tracked in this index fall within that class or its catch-all clause. The list is revised annually and takes effect on 1 January. PepIndex records revisions affecting indexed compounds here.
The phrase is a label a seller applies, not a status a regulator confers. It can support a claim that a product is not intended for human use, and where a seller’s conduct is consistent with it, that matters. What it cannot do is outweigh the rest of the evidence about intended use — the marketing copy, the imagery, the testimonials, the search terms a listing is written for. Regulators in the United States and the United Kingdom both read intended use from the whole record rather than from the disclaimer.
Where a substance is controlled at ingredient level, the label does nothing at all. A Schedule 4 substance under the Australian Poisons Standard is Schedule 4 in a vial marked for research, and an ingredient on Canada’s Prescription Drug List carries its prescription requirement however the product containing it is described.
The practical consequence for a reader is narrow but real: the phrase tells you something about how a seller positions itself and nothing about what is in the vial. That second question is answered by a certificate — see how to read a peptide certificate of analysis.
Approval status of the compounds tracked here
67 compounds
Legality questions usually arrive attached to a specific compound, and the answer differs sharply between a substance with an approved counterpart and one that has never been approved anywhere. Below is the status statement the index records against each tracked compound, grouped. Approval is jurisdiction-specific and it moves; the compound page is the record.
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
Abaloparatide is an approved prescription medicine in one or more of the United States, United Kingdom and European Union. When listed by the vendors in this index it is labeled for laboratory research use only, and nothing here is medical advice or an endorsement of human use.
Approved as a prescription medicine in several jurisdictions. Research-grade material listed by indexed vendors is labeled for laboratory research use only and is not the approved product.
Approved as a prescription medicine in several jurisdictions. Research-grade material listed by indexed vendors is labeled for laboratory research use only.
Cerebrolysin is approved as a medicine in some countries but not in the United States. Products listed here are labeled by their vendors for laboratory research use only, and nothing here is medical advice.
Eloralintide is an investigational compound in clinical development and is not an approved medicine in the United States, United Kingdom or European Union. Products listed here are labeled by their vendors for laboratory research use only.
Human chorionic gonadotropin is an approved prescription medicine in one or more of the United States, United Kingdom and European Union. When listed by the vendors in this index it is labeled for laboratory research use only, and nothing here is medical advice or an endorsement of human use.
L-carnitine is an approved prescription medicine in one or more of the United States, United Kingdom and European Union. When listed by the vendors in this index it is labeled for laboratory research use only, and nothing here is medical advice or an endorsement of human use.
Larazotide is an investigational compound in clinical development and is not an approved medicine in the United States, United Kingdom or European Union. Products listed here are labeled by their vendors for laboratory research use only.
Mazdutide is approved as a medicine in some countries but not in the United States. Products listed here are labeled by their vendors for laboratory research use only, and nothing here is medical advice.
Mecasermin is an approved prescription medicine in one or more of the United States, United Kingdom and European Union. When listed by the vendors in this index it is labeled for laboratory research use only, and nothing here is medical advice or an endorsement of human use.
Menotropins is an approved prescription medicine in one or more of the United States, United Kingdom and European Union. When listed by the vendors in this index it is labeled for laboratory research use only, and nothing here is medical advice or an endorsement of human use.
Metformin is an approved prescription medicine in one or more of the United States, United Kingdom and European Union. When listed by the vendors in this index it is labeled for laboratory research use only, and nothing here is medical advice or an endorsement of human use.
Methylene blue is an approved prescription medicine in one or more of the United States, United Kingdom and European Union. When listed by the vendors in this index it is labeled for laboratory research use only, and nothing here is medical advice or an endorsement of human use.
Orforglipron is an investigational compound in clinical development and is not an approved medicine in the United States, United Kingdom or European Union. Products listed here are labeled by their vendors for laboratory research use only.
Oxytocin is an approved prescription medicine in one or more of the United States, United Kingdom and European Union. When listed by the vendors in this index it is labeled for laboratory research use only, and nothing here is medical advice or an endorsement of human use.
Sirolimus is an approved prescription medicine in one or more of the United States, United Kingdom and European Union. When listed by the vendors in this index it is labeled for laboratory research use only, and nothing here is medical advice or an endorsement of human use.
Sold in various regulatory categories depending on jurisdiction and form. Research-grade material listed by indexed vendors is labeled for laboratory research use only.
Somatropin is an approved prescription medicine in one or more of the United States, United Kingdom and European Union. When listed by the vendors in this index it is labeled for laboratory research use only, and nothing here is medical advice or an endorsement of human use.
Tesofensine is an investigational compound in clinical development and is not an approved medicine in the United States, United Kingdom or European Union. Products listed here are labeled by their vendors for laboratory research use only.
Thymalin is approved as a medicine in some countries but not in the United States. Products listed here are labeled by their vendors for laboratory research use only, and nothing here is medical advice.
Triptorelin is an approved prescription medicine in one or more of the United States, United Kingdom and European Union. When listed by the vendors in this index it is labeled for laboratory research use only, and nothing here is medical advice or an endorsement of human use.
Used in regulated cosmetic products in some jurisdictions. Research-grade material listed by indexed vendors is labeled for laboratory research use only.
Every compound page carries the published research behind the substance and the vendors indexed as carrying it. The regulatory feed records dated actions affecting them, each linked to the issuing body’s own page.
How to check any of this yourself
Every source used above is a primary one, published by the body that administers the rule. Regulatory positions move, and a secondary summary — this one included — is only as current as its last revision. These are the registers worth checking directly:
Is there an approved counterpart? The EMA medicines register and its national equivalents state whether a substance has been authorised as a medicine at all, which determines whether the trial literature describes the product being sold.
Is the ingredient scheduled?The Australian Poisons Standard and Canada’s Prescription Drug List name ingredients rather than brands, and are the two registers here that bite regardless of presentation.
Has the regulator acted before?The FDA warning-letter database and the MHRA’s published positions record enforcement against named sellers and named substances.
Does it matter for sport? The WADA Prohibited List is revised annually and takes effect on 1 January.
In the jurisdictions covered here, buying a peptide sold and labelled as a laboratory research reagent is not in itself the regulated act. What is regulated is supplying, advertising or importing it as a medicine — and in Australia and Canada, additionally, whether the ingredient itself is scheduled or prescription-only. Legality follows the presentation and the border crossing rather than the molecule.
Is it legal to buy research peptides in the United States?
The FD&C Act defines a drug by intended use, established from objective evidence including labelling and marketing. A peptide sold as a laboratory reagent with no human-use claim is not being marketed as a drug; the same product sold with a claim about what it does in people is an unapproved new drug and is treated as misbranded. Personal importation is a matter of FDA enforcement discretion, not an entitlement.
Are peptides legal in the UK?
Under the Human Medicines Regulations 2012 a product is a medicinal product either by presentation or by function, and placing one on the UK market without a marketing authorisation is an offence. The function limb means a product can fall within the definition without any health claim being made about it. The MHRA has acted on that basis against melanotan products over a period of years.
Are peptides legal in Australia?
Australia is the strictest of the six regimes covered here. Therapeutic goods must be entered on the Australian Register of Therapeutic Goods before import or supply unless exempt, and the Poisons Standard schedules substances directly — peptide hormones and growth factors commonly as Schedule 4, prescription-only. Personal importation of a prescription-only medicine requires a valid Australian prescription held at the time of import.
What does "research use only" mean legally?
It is a label a seller applies, not a category a regulator grants. The phrase can support a claim that a product is not intended for human use, but it does not outweigh the rest of the evidence about intended use, and it confers no permission by itself. Where a substance is controlled at ingredient level, as under the Australian Poisons Standard, the label has no effect at all.
Is it legal to import peptides for personal use?
Import is governed separately from sale in every jurisdiction here. The United States treats personal importation as enforcement discretion; Canada applies published personal-use guidance narrowly; Australia’s Personal Importation Scheme permits import of unapproved goods under conditions but requires an Australian prescription for anything prescription-only, with quantity limits. None of these is a general permission.
Does PepIndex say whether a specific purchase is legal?
No. This page records what the named regulators publish and links every statement to its primary source. It is not legal advice, it assesses no particular transaction, and it makes no safety or efficacy claim about any substance. Legal exposure depends on facts a website cannot see.
Not legal advice
This page records what the regulators named above publish, and links each statement to its source. It is not legal advice, it does not assess any particular transaction or any jurisdiction beyond those covered, and regulatory positions change — several of the registers cited here are revised on a rolling basis. Anyone with a real exposure should take advice from someone qualified in the relevant jurisdiction rather than from a reference site.
Every product indexed on PepIndex is labeled by its vendor for laboratory research use only. Nothing here is medical advice, a recommendation of human use, or a dosing or protocol suggestion — PepIndex publishes none of that anywhere, and makes no safety or efficacy claim about any substance. See the full disclosure and terms.